EQRX INC (EQRX)

Company Profile

EQRx, Inc. is a pharmaceutical company, which engages in developing and delivering innovative medicines to patients having chronic conditions. The company is headquartered in Cambridge, Massachusetts and currently employs 362 full-time employees. The company went IPO on 2021-04-09. The firm is engaged in developing medicines for some of the prevalent disease areas, including cancer and immune-inflammatory conditions. The firm brands include EQRx and Remaking Medicine. The firm's pipeline is comprised of approximately 10 programs, including both small molecules and biologics, with five clinical-stage programs, and several disclosed and undisclosed preclinical and drug engineering programs. Its clinical programs include Aumolertinib (EQ143), Lerociclib (EQ132), and Sugemalimab (EQ165). Aumolertinib (EQ143) is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). Lerociclib (EQ132) is a novel and oral small molecule cyclin-dependent kinase (CDK) 4/6 inhibitor. Sugemalimab (EQ165, also known as CS1001) is an anti-programmed cell death-ligand 1 (PD-L1) monoclonal antibody.

Company Info

EQRX INC

50 Hampshire Street

Cambridge MASSACHUSETTS

P: 16173152255.0

Employees: 362

Website: https://www.eqrx.com/